Want to see KR:033270 full AI Analyst Report?
KOREA UNITED PHARM, INC. (033270) Ratios
KOREA UNITED PHARM, INC. Ratios
KR:033270's free cash flow for Q2 2026 was $12.51B. For the 2026 fiscal year, KR:033270's free cash flow was decreased by $-1.47B and operating cash flow was $13.97B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.63 | 5.08 | 3.37 | 3.41 | 3.36 |
| Quick Ratio | 4.28 | 3.79 | 2.69 | 2.78 | 2.66 |
| Cash Ratio | 0.84 | 0.70 | 0.33 | 0.41 | 1.00 |
| Solvency Ratio | 0.77 | 0.65 | 0.65 | 0.67 | 0.45 |
| Operating Cash Flow Ratio | 1.07 | 0.56 | 0.70 | 0.97 | 0.72 |
| Short-Term Operating Cash Flow Coverage | 25.46 | 15.31 | 1.78 | 2.90 | 2.22 |
| Net Current Asset Value | $ 203.85B | $ 177.03B | $ 154.56B | $ 144.36B | $ 125.03B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.03 | 0.09 | 0.07 | 0.09 |
| Debt-to-Equity Ratio | 0.03 | 0.04 | 0.11 | 0.09 | 0.11 |
| Debt-to-Capital Ratio | 0.03 | 0.04 | 0.10 | 0.08 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.03 | 0.03 | 0.02 | 0.04 |
| Financial Leverage Ratio | 1.14 | 1.17 | 1.24 | 1.24 | 1.26 |
| Debt Service Coverage Ratio | 22.44 | 19.78 | 1.96 | 2.35 | 1.75 |
| Interest Coverage Ratio | 281.78 | 116.19 | 33.94 | 59.12 | 66.20 |
| Debt to Market Cap | 0.04 | 0.05 | 0.10 | 0.09 | 0.05 |
| Interest Debt Per Share | 869.24 | 1098.05 | 2867.18 | 2101.39 | 2256.45 |
| Net Debt to EBITDA | -0.43 | -0.31 | 0.23 | 0.06 | -0.60 |
| Profitability Margins | |||||
| Gross Profit Margin | 60.74% | 56.79% | 56.99% | 55.34% | 55.49% |
| EBIT Margin | 16.94% | 16.13% | 21.76% | 20.21% | 17.75% |
| EBITDA Margin | 20.94% | 20.04% | 25.37% | 23.53% | 21.09% |
| Operating Profit Margin | 16.94% | 19.49% | 19.70% | 18.37% | 15.03% |
| Pretax Profit Margin | 17.25% | 15.96% | 21.54% | 20.35% | 17.86% |
| Net Profit Margin | 13.27% | 11.24% | 17.30% | 17.25% | 12.96% |
| Continuous Operations Profit Margin | 13.27% | 11.24% | 17.30% | 17.25% | 12.96% |
| Net Income Per EBT | 76.89% | 70.41% | 80.32% | 84.75% | 72.56% |
| EBT Per EBIT | 101.86% | 81.89% | 109.34% | 110.81% | 118.83% |
| Return on Assets (ROA) | 7.37% | 6.85% | 10.29% | 10.83% | 7.54% |
| Return on Equity (ROE) | 8.43% | 7.99% | 12.74% | 13.40% | 9.53% |
| Return on Capital Employed (ROCE) | 10.37% | 13.22% | 13.87% | 13.70% | 10.41% |
| Return on Invested Capital (ROIC) | 7.94% | 9.27% | 10.39% | 10.92% | 7.11% |
| Return on Tangible Assets | 7.53% | 6.98% | 10.50% | 11.07% | 7.69% |
| Earnings Yield | 12.30% | 12.13% | 11.97% | 13.44% | 4.08% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.20 | 5.81 | 0.00 | 6.48 | 5.98 |
| Payables Turnover | 12.93 | 19.20 | 14.82 | 14.03 | 15.47 |
| Inventory Turnover | 1.76 | 2.01 | 2.44 | 2.85 | 2.32 |
| Fixed Asset Turnover | 1.69 | 1.82 | 1.80 | 1.92 | 1.83 |
| Asset Turnover | 0.56 | 0.61 | 0.59 | 0.63 | 0.58 |
| Working Capital Turnover Ratio | 1.38 | 1.57 | 1.69 | 1.74 | 1.67 |
| Cash Conversion Cycle | 237.57 | 225.32 | 124.89 | 158.20 | 194.93 |
| Days of Sales Outstanding | 58.90 | 62.86 | 0.00 | 56.36 | 61.09 |
| Days of Inventory Outstanding | 206.90 | 181.48 | 149.52 | 127.86 | 157.43 |
| Days of Payables Outstanding | 28.23 | 19.01 | 24.63 | 26.01 | 23.59 |
| Operating Cycle | 265.80 | 244.33 | 149.52 | 184.22 | 218.52 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3130.83 | 1823.72 | 3461.03 | 4307.70 | 2970.05 |
| Free Cash Flow Per Share | 1695.61 | 379.25 | 1321.55 | 2672.79 | 2108.45 |
| Dividend Paid and CapEx Coverage Ratio | 1.70 | 0.98 | 1.36 | 2.15 | 2.45 |
| Capital Expenditure Coverage Ratio | 2.18 | 1.26 | 1.62 | 2.63 | 3.45 |
| Operating Cash Flow Coverage Ratio | 3.65 | 1.71 | 1.26 | 2.11 | 1.34 |
| Operating Cash Flow to Sales Ratio | 0.18 | 0.09 | 0.18 | 0.24 | 0.20 |
| Free Cash Flow Yield | 8.89% | 2.08% | 4.80% | 11.75% | 4.45% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 7.29 | 8.25 | 8.35 | 7.44 | 24.53 |
| Price-to-Sales (P/S) Ratio | 1.08 | 0.93 | 1.45 | 1.28 | 3.18 |
| Price-to-Book (P/B) Ratio | 0.69 | 0.66 | 1.06 | 1.00 | 2.34 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 11.25 | 48.02 | 20.85 | 8.51 | 22.46 |
| Price-to-Operating Cash Flow Ratio | 6.09 | 9.99 | 7.96 | 5.28 | 15.94 |
| Price-to-Earnings Growth (PEG) Ratio | 0.39 | -0.25 | 1.06 | 0.13 | 3.23 |
| Enterprise Value Multiple | 4.72 | 4.31 | 5.93 | 5.51 | 14.48 |
| Enterprise Value | 285.22B | 249.49B | 419.59B | 340.25B | 674.99B |
| EV to EBITDA | 4.72 | 4.31 | 5.93 | 5.51 | 14.48 |
| EV to Sales | 0.99 | 0.86 | 1.50 | 1.30 | 3.05 |
| EV to Free Cash Flow | 10.30 | 44.78 | 21.70 | 8.60 | 21.57 |
| EV to Operating Cash Flow | 5.58 | 9.31 | 8.28 | 5.33 | 15.31 |
| Tangible Book Value Per Share | 27189.60 | 27020.40 | 25238.44 | 22223.21 | 19769.31 |
| Shareholders’ Equity Per Share | 27833.31 | 27648.18 | 25876.91 | 22818.09 | 20258.97 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.30 | 0.20 | 0.15 | 0.27 |
| Revenue Per Share | 17678.76 | 19650.61 | 19061.40 | 17730.16 | 14891.62 |
| Net Income Per Share | 2345.29 | 2208.89 | 3297.93 | 3057.78 | 1930.09 |
| Tax Burden | 0.77 | 0.70 | 0.80 | 0.85 | 0.73 |
| Interest Burden | 1.02 | 0.99 | 0.99 | 1.01 | 1.01 |
| Research & Development to Revenue | 0.12 | 0.06 | 0.12 | 0.06 | 0.06 |
| SG&A to Revenue | 0.14 | 0.13 | 0.13 | 0.13 | 0.15 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.33 | 0.83 | 1.05 | 1.41 | 1.54 |
Currency in KRW